Olimpia Baranowska — CEO & Scientific Director, Olympia Biosciences™

CEO & Scientific Director,

Olimpia Baranowska

Olimpia Baranowska is a technical physicist, PhD candidate in Medicine, and architect of Europe's Zero-Conflict CDMO model. As CEO and Scientific Director of Olympia Biosciences™ Ltd. (Olympia Biosciences™), she has built a 17-year contract manufacturing organization with zero quality complaints — recognized at the International Businesswoman Awards in Rome and by Poland's National Centre for Research and Development.

Executive Summary

Architect of the Zero-Conflict CDMO model in Europe.

She co-founded International Organic Company (Olympia Biosciences™ Ltd.) in 2009 and has led the company through 17 years of uninterrupted operation with zero quality complaints — — a record virtually unmatched in the global contract manufacturing sector.

Her unique combination of technical physics, applied mathematics, and medical science enables an interdisciplinary approach to formulation design. It bridges quantum-level molecular understanding (biophysics of absorption) with practical clinical efficacy. Under her leadership, Olympia Biosciences™ pioneered the integration of proprietary AI models for toxicological prediction in supplement manufacturing — a pharma-grade verification layer that no other CDMO employs.

Every enterprise-level formulation project at Olympia Biosciences™ is personally overseen by our executive leadership. Apply for a rigorous technology audit to begin the process.

Academic Pedigree

MSc Eng. Technical Physics & Applied Mathematics

Gdansk University of Technology

Rigorous background in quantum physics and applied mathematics, providing the foundation for Olympia Biosciences™'s proprietary AI algorithms.

PhD Candidate in Medicine

Medical University of Gdansk

Ongoing doctoral research at the strict intersection of biophysics, pharmacogenetics, and clinical supplementation efficacy.

Key Innovations

Zero Conflict policy

She is the architect of Olympia Biosciences™'s Zero Conflict policy. The company operates exclusively as a contract manufacturer with no consumer brands, ensuring absolute loyalty to clients' intellectual property. This model was recognized at the International Businesswoman Awards in Rome and under the patronage of the National Centre for Research and Development.

AI Toxicological Prediction

Developed an AI model trained on hundreds of thousands of medical papers for ingredient interaction screening and cocktail effect analysis.

"The industry standard was to quietly reverse-engineer client success. We built a facility to protect it."

Cambridge Tech Transfer

Selected by the University of Cambridge and Adiuvo S.A. for exclusive industrial scale-up of precision micellar delivery systems.

Vegicoll® — Plant-Based Collagen

Co-developed the world's first plant-based collagen analog with hard hydroxyproline. Registered trademark Z.566783.

A decade of recognized excellence.

International Leader in Scientific Excellence

International Businesswoman Awards, Rome

Awarded for scientific leadership and the Zero Conflict manufacturing model.

Best in Business Award

NCBiR Patronage (National R&D Centre)

Recognition for ethical business practices and innovation in nutraceutical manufacturing.

Business Growth Award — Chemical Industry

European Business Institute

Top dynamic growth in the chemical industry sector.

5,000 Most Dynamic Companies in Poland

European Business Institute

National ranking of fastest-growing enterprises.

Business Growth Award — Chemical Industry (2021)

European Business Institute

Consecutive year of recognition for dynamic growth (1966% dynamics).

Business Growth Award — Regional

European Business Institute

Regional leader in business growth.

Effective Company — Chemical Industry

European Business Institute

Recognition for operational efficiency and multi-year financial stability.

Featured In Media

Algorithm in a Capsule

Feature on Olympia Biosciences™'s proprietary AI model for toxicological prediction in supplement manufacturing.

Collagen Vege Presentation

Presentation of the world's first plant-based collagen analog, co-developed by Olimpia Baranowska.

0

zero quality complaints

— a record virtually unmatched in the global contract manufacturing sector.

“The industry standard was to quietly reverse-engineer client success. We built a facility to protect it.”

Olimpia Baranowska

CEO & Scientific Director,

Verification

Olimpia Baranowska: MSc Eng. Technical Physics & Applied Mathematics — Gdansk University of Technology. PhD Candidate in Medicine — Medical University of Gdansk.

Work directly with our scientific team.

Every enterprise-level formulation project at Olympia Biosciences™ is personally overseen by our executive leadership. Apply for a rigorous technology audit to begin the process.

Frequently Asked Questions

Who is Olimpia Baranowska and what is her role at Olympia Biosciences™?
Olimpia Baranowska (MSc Engineering) is the Co-Founder, CEO, and Scientific Director of Olympia Biosciences™ (Olympia Biosciences™ Ltd.). She holds a Master's degree in Technical Physics from Gdansk University of Technology and is a PhD candidate in Medicine at the Medical University of Gdansk. She is the architect of the Zero Conflict CDMO model and pioneer of AI-verified toxicological screening in supplement manufacturing.
What is the Zero Conflict of Interest model that Olimpia Baranowska developed?
The Zero Conflict of Interest model is a corporate policy ensuring Olympia Biosciences™ never develops, manufactures, or markets supplement products under its own consumer brand. This eliminates any competitive conflict with clients whose formulas we develop. Combined with ISO 27001:2023 information security, it creates the strongest possible IP protection for B2B partners.
What scientific publications has Olimpia Baranowska authored?
Olimpia Baranowska has authored peer-reviewed and industry publications on collagen science (Biotechnologia.pl — 3 papers), pharmacogenetics and personalized medicine (Pharmaceutical Industry World), nervous system supplementation, hyperbaric oxygen therapy (Practical Physiotherapy), and collagen market analysis. Her research spans nutraceutical chemistry, biophysics, and clinical applications.
What international awards has Olimpia Baranowska and Olympia Biosciences™ received?
Recognition includes: International Leader in Scientific Excellence (International Businesswoman Awards, Rome), Best in Business Award under NCBiR Patronage (National R&D Centre, Poland), three consecutive Business Growth Awards in the Chemical Industry (European Business Institute), regional growth leader, recognition among the 5,000 Most Dynamic Companies in Poland, and Effective Company in the Chemical Industry.